ストックスクリーナーアプリを入手
2.39
3.24%
-0.08
アフターアワーズ：
2.36
-0.03
-1.26%
前日終値:
$2.47
開ける：
$2.42
24時間の取引高:
50,717
Relative Volume:
0.61
時価総額：
$5.60M
収益：
$3.19M
当期純損益:
$-2.23M
株価収益率:
-1.9442
EPS:
-1.2293
ネットキャッシュフロー:
$-1.82M
1週間 パフォーマンス:
-13.72%
1か月 パフォーマンス:
-37.43%
6か月 パフォーマンス:
-20.07%
1年 パフォーマンス:
-26.23%
1日の値動き範囲:
$2.3302
$2.5304
1週間の範囲:
$2.28
$3.10
52週間の値動き範囲:
$1.87
$13.93
Xenetic Biosciences Inc Stock (XBIO) Company Profile
名前
Xenetic Biosciences Inc
セクター
電話
781-778-7720
住所
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.39 | 5.60M | 3.19M | -2.23M | -1.82M | -1.2293 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-08 | 開始されました | Maxim Group | Buy |
Xenetic Biosciences Inc (XBIO) 最新ニュース
Xenetic Updates Investors on Santersus Share Exchange Plans - TipRanks
Form 8K Xenetic Biosciences Inc For: 23 September - Investing.com India
Form 8K Xenetic Biosciences Inc For: 23 September By Investing.com - Investing.com UK
Santersus holders could own about 85% of the combined company in Xenetic Biosciences (XBIO)'s pending exchange. - Stock Titan
Xenetic to acquire Santersus in NET-targeting biotech combination - AllSci
Dig: Santersus Xenetic Sep MERGER premature — close ~Q4 2026 - Dealroom
Xenetic Biosciences (XBIO) investor reports 0% holding - Stock Titan
Form 8K Xenetic Biosciences Inc For: 16 September By Investing.com - Investing.com South Africa
Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake - Yahoo Finance
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition - Yahoo Finance
Xenetic Biosciences to Merge With Santersus in All-Stock Deal - Minichart
Xenetic Biosciences and Santersus AG agree to create a global leader in therapies against NETs - Demócrata
[SUPERSEDED by Dig 154759] Xenetic to merge with Santersus, ceding 85% of combined biotech to Swiss investors - Dealroom.co
Xenetic Biosciences to Acquire Santersus in All-Stock NET Therapeutics Deal - citybiz
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Xenetic Biosciences to acquire Santersus in all-stock deal By Investing.com - Investing.com Nigeria
XBIO Looks 12.4% Overvalued on GF Value™ as Market Prices in Hig - gurufocus.com
Xenetic Biosciences to Acquire Santersus AG in Merger - TipRanks
Xenetic Biosciences to acquire Santersus in all-stock deal - Investing.com
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics - ACCESS Newswire
Santersus deal would leave Xenetic Biosciences (NASDAQ: XBIO) owners with 15% - Stock Titan
A planned biotech deal would unite four clinical programs around one disease driver - Stock Titan
Xenetic Biosciences Inc. Warrants (XBIOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Xenetic Biosciences Inc. Warrants (XBIOW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xenetic Biosciences Inc. Warrants (XBIOW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xenetic Biosciences, Inc. Revenue Breakdown – NASDAQ:XBIO - TradingView
XBIO Q2 2025 Earnings: Narrower-Than-Expected Loss of -$0.45 Beats Estimates by 31.07%Financial Health Score - vinanet.vn
Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicense - TradingView
Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss - TradingView
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - Yahoo Finance
Xenetic Biosciences: Q2 Earnings Snapshot - marketscreener.com
XBIO Q2 2025 Earnings: Narrower Loss of $0.45 Per Share Beats Estimates by 31.07%Profit Inflection Point - dars.gov.et
Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary - tradingview.com
Xenetic Biosciences (XBIO) Rises 3.31% to $2.81, Approaching Key Resistance at $2.95TWAP Entry - dars.gov.et
XBIO Q2 2025 Earnings: Narrower Loss of $0.45 per Share Beats Estimates Despite No RevenueEarnings Expansion Phase - careplusvn.com
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - dars.gov.et
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: EPS Beat Driven by Cost Discipline Amid Clinical-Stage Operations - careplusvn.com
Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIO|Xenetic Biosciences Inc|Price:2.640|Chg%:-0.085 - TradingKey
Xenetic Biosciences Inc (XBIO) Cash Flow - TradingKey
Xenetic Biosciences Inc (XBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBIO Q2 2025 Earnings: Narrower-Than-Expected Loss Drives Stock HigherFinal Results - dars.gov.et
Xenetic Biosciences (XBIO) Slides 1% as Shares Approach Key SupportTurnaround Stocks - vinanet.vn
Xenetic Biosciences (XBIO) Rises 3.58% as Biotech Stock Nears Key ResistanceSize Factor - dars.gov.et
Number of shareholders of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Price to book forward of Xenetic Biosciences, Inc. – NASDAQ:XBIO - TradingView
Xenetic Biosciences Inc (XBIO) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):